-
Soybean oil based lipid emulsion, is rich in essential fatty acids (linoleic and α-linolenic acid).
-
Provides high amounts of energy Longest and broadest experience since 1962
-
Excellent mixing properties and well tolerated in a wide range of clinical conditions
-
Extensive compatibility and stability data are available with a wide range of admixtures
-
Application via peripheral veins possible
-
Intralipid® is indicated in patients needing intravenous nutrition to supply energy and essential fatty acids.
-
Intralipid® is also indicated in patients with essential fatty acid deficiency (EFAD) who cannot maintain or restore a normal essential fatty acid pattern by oral intake.
-
Paediatric indication for Intralipid 10% and 20%.
-
10% (500ml), 20% (100ml, 250ml and 500ml) Intralipid glass bottles
-
Prematures and low birthweight neonates: initially 0.5 - 1 g/kg body wt/day followed by a successive increase by 0.5-1 g/kg body wt/day up to 2g/kg bw/day.
-
Neonates and infants: 0.5-4 g TG/kg body wt/day.
-
Adults : up to 3 g TG/kg body wt/day
-
Highly reliable and of a high quality Extensively documented in a huge number of publications Well-tolerated in a wide range of clinical conditions Similar impact on important parameters with respect to
-
clinical outcome
-
liver cell function and integrity
-
immune and inflammatory response
-
antioxidant status and oxidative stress
-
compared to other standard lipid emulsions (MCT/LCT physical mixture and olive/soybean oil emulsion)
-
Lipids are both a concentrated energy substrate and a source of essential fatty acids. Parenteral nutrition gets more physiological through the inclusion of Intralipid® in combination with glucose in a balanced energy system (Dual-energy system).
-
The key advantages of the dual-energy system are:
-
Minimises hyperglycemia
-
Reduces metabolic stress
-
Improves protein utilisation
-
Prevents fatty infiltration of the liver
-
Preserves hepatic function
-
Reduces respiratory stress
-
Singer P et al. Clin Nutr 2009, 28:387–400
-
Nordenström J et al. Clin Physiol 1981, 1:525–534
-
Garcia-de-Lorenzo A et al. JPEN 2003, 27:208–215
-
Demling RH et al. J Burn Care Rehabil 1985, 6:222–225
-
Enzi G et al. Crit Care Med 1990, 18:719–721
-
Roulet M et al. Clin Nutr 1983, 2:97–105
-
Nanni G et al. J Trauma 1984, 24:14–30
-
Caresta E et al. Pediatr Res 2007, 61:228–232
-
Kalfarentzos F et al. Clin Nutr 1998, 17:31–34
-
Puiggros C et al. Enteral Nutr 2009, 33:501–512
-
Dionigi P et al. Clin Nutr 1985, 4:229–234
-
Shaw JH et al. Enteral Nutr 1988, 12:433–440
-
Nagayama M et al. Nutrition 1991, 7:267–270
-
Socha P et al. Nutrition 2007, 23:121–126
-
Korzets A et al. J Ren Nutr 1999, 9:206–213
-
Lee HA et al. Postgrad Med J 1967, 43:81–91
-
Szczygiel B et al. J Clin Nutr Gastroenterol 1991, 6:203–213
-
Silberman H et al. Am J Gastroenterol 1982, 77:494–497
-
Wu H et al. Zhonghua Wai Ke Za Zhi 1995, 33:261–264
-
Goulet O et al. Am J Clin Nutr 1999, 70:338–345
-
Webb AN et al. Nutrition 2008, 24:1057–1064
-
Deshpande GC et al. J Pediatr Gastroenterol Nutr 2009, 49:619–625
-
Göbel Y et al. J Pediatr Gastroenterol Nutr 2003, 37:161–167
-
Bouletreau P et al. Nutr Clin Metabol 1996, 10:33–36
-
Garnacho-Montero J et al. Nutrition 2002, 18:134–138
-
Chen FM et al. Kaohsiung J Med Sci 2005, 21:487–494
-
Mateu-de Antonio J et al. Br J Nutr 2008, 99:846–854
-
Goulet O et al. Nutrition 1992, 8:333–337
-
Wirtitsch M et al. Clin Nutr 2007, 26:302–313
-
Reimund JM et al. Aliment Pharmacol Ther 2005, 21:445–454
-
Roggero P et al. Nutrition 2009 online
-
Cipierre C et al. Acta Pediatrica 2009, 98:44–45
-
Tulikoura I et al. Scand J Gastroenterol 1982, 17:177–185
-
Buchmiller CE et al. JPEN 1993, 17:301–306
-
Askanazi J et al. Anesthesiology 1981, 54:373–377
-
Braga M et al. Clin Nutr 2009, 28:378–386
-
Ziegler TR. N Engl J Med 2009, 361:1088–1097